Credit Suisse downgraded Teva Pharma (NYSE: TEVA) from Outperform to Neutral with a price target of $25.00 (from $39.00).Analyst Vamil ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE